Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

Imagine if you can get your $100 million athlete back before the end of the season,” said Dr. Paul Liu, executive chairman of Pax Therapeutics.

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

The company believes the Food and Drug Administration may deal a setback to one of its investigational therapies.

There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector system will be used, with AAV and lentivirus being two of the most commonly ...

Otsuka Pharma enters licensing agreement with 4D Molecular Therapeutics for ophthalmic gene therapy drug candidate, 4D-150: Tokyo Monday, November 3, 2025, 11:00 Hrs [IST] Otsuka ...

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...

This growth is fueled by the escalating demand for biologics and biosimilars, continued innovation in cell line engineering, and increasing applications in gene therapy ... rapidly as biotechnology ...

WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really ...